The Equine Herpesvirus 1 UL45 Homolog Encodes a Glycosylated Type II Transmembrane Protein and Is Involved in Virus Egress  by Oettler, Dirk et al.
2Virology 279, 302–312 (2001)
doi:10.1006/viro.2000.0690, available online at http://www.idealibrary.com onThe Equine Herpesvirus 1 UL45 Homolog Encodes a Glycosylated Type II
Transmembrane Protein and Is Involved in Virus Egress
Dirk Oettler, Oskar-Ru¨ger Kaaden, and Antonie Neubauer1
Institute for Medical Microbiology, Infectious and Epidemic Diseases, Ludwig-Maximilians-Universita¨t Mu¨nchen,
Veterina¨rstr. 13, D-80539 Munich, Germany
Received August 15, 2000; returned to author for revision September 26, 2000; accepted October 6, 2000
Experiments to analyze the product of the equine herpesvirus type 1 (EHV-1) UL45 homolog were conducted. Using an
antiserum generated against the carboxylterminal 114 amino acids of the EHV-1 UL45 protein, proteins of Mr 32,000, 40,000,
and 43,000 were detected specifically in EHV-1-infected cells. Neither form of the protein was located in purified virions of
EHV-1 wild-type strain RacL22 or the modified live vaccine strain RacH, but UL45 was demonstrated to be expressed as a
late (g22) protein. Fractionation of infected cells and deglycosylation experiments demonstrated that the EHV-1 UL45 protein
represents a type II membrane glycoprotein. Deletion of the UL45 gene in RacL22 and RacH (LD45 and HD45) showed that
UL45 is nonessential for EHV-1 growth in vitro, but that deletion reduced the viruses’ replication efficiency. A marked
reduction of virus release was observed although no significant influence was noticed either on plaque size or on the
syncytial phenotype of the EHV-1 strain RacH. © 2001 Academic Press
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pINTRODUCTION
The Alphaherpesvirus equine herpesvirus type 1
(EHV-1) is an important pathogen of horses that causes
rhinopneumonitis, late-term abortions, and neurological
disorders (Allen and Bryans, 1986). At least 76 proteins
are encoded by EHV-1 (Telford et al., 1992), most of
which, especially the structural proteins, are conserved
in the subfamily of the Alphaherpesvirinae. Twelve EHV-1
glycoproteins have been described and are named in
accordance with membrane glycoproteins of herpes sim-
plex virus 1 (HSV-1). Among these glycoproteins are
homologs to glycoproteins B, C, D, E, G, H, I, K, L, and M,
whereas glycoprotein 1/2 is unique for EHV-1 (Oster-
rieder et al., 1999). Another glycosylated protein (gp10),
the homolog of HSV-1 VP13/14, is not part of the viral
envelope but is a component of the tegument (Whittaker
et al., 1991). In addition, several open reading frames
(ORF) in Alphaherpesvirinae have been identified that
could encode for additional membrane-associated pro-
teins, some of which are carrying glycosylation consen-
sus sites. Among these ORFs are homologs of the HSV-1
UL45 that have been described in HSV-2 (Cockrell and
Muggeridge, 1998), several avian herpesviruses like
Marek’s disease virus, and herpesvirus of turkeys (Kato
et al., 1989) or infectious laryngotracheitis virus (ILTV,
Ziemann et al., 1998), but also in feline herpesvirus 1
(FHV-1, Willemse et al., 1994) and in EHV-1 and EHV-4i
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302(Telford et al., 1992, 1998). Besides EHV-1 and EHV-4,
however, no UL45 homologous ORFs have been de-
tected in the genomes of such Varicelloviruses as vari-
cella-zoster virus (Davison and Scott, 1986), bovine her-
pesvirus 1 (Schwyzer et al., 1996), and pseudorabies
virus (PrV, Bras et al., 1999). The amino acid homology
between the predicted UL45 gene products is moderate,
but they all contain a large internal hydrophobic domain
(Ihara et al., 1989; McGeoch et al., 1988; Willemse et al.,
1994; Cockrell and Muggeridge, 1998; Telford et al., 1998;
Ziemann et al., 1998). The Mr 18,000 UL45 protein of
HSV-1, a component of the virion, was classified as a true
late protein, the expression of which is dependent on
DNA synthesis (Visalli and Brandt, 1993), whereas the
75% identical UL45 of HSV-2 was detected as early as 4 h
p.i. (Cockrell and Muggeridge, 1998). The latter localizes
to cellular membranes in transfected Cos7 cells, in a
pattern resembling the endoplasmatic reticulum (ER), but
not to the cell-surface membrane. It was shown to be an
integral type II membrane protein (Cockrell and Mug-
geridge, 1998). Another type II membrane protein en-
coded by the US9 homolog of PrV was identified. The
role of the uniquely tail-anchored US9 protein in the PrV
life cycle is still under investigation, but it was shown to
have an effect on virus spread in the rat nervous system
(Brideau et al., 1998, 2000). Haanes et al. (1994) analyzed
the effect of HSV-1 UL45 on the formation of gB-induced
fusion observed in several HSV-1 syn mutants, and the
rotein was shown to be a mediator of fusion events late
n HSV-1 infection. Insertion of a marker gene into the
L45 genes of HSV-1 or FHV-1 demonstrated that the
t
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303EHV-1 UL45 PROTEIN IDENTIFICATION AND CHARACTERIZATIONprotein is nonessential for replication of these viruses.
While the HSV-1 mutant exhibited an influence on the
plaque phenotype, no in vitro phenotype was reported for
he FHV-1 mutant virus that replicated efficiently in cats
Visalli and Brandt, 1991; Willemse et al., 1994). Despite
that, the FHV-1 UL45 mutant did not cause FHV-1-related
symptoms and was identified as a virulence factor (Wil-
lemse et al., 1994).
Information on the structure and the function of several
UL45 homologs has been acquired, but the proteins’
functions are not yet fully understood. Therefore, the
aims of this study were to determine the expression, the
posttranslational modification(s), and the function of the
EHV-1 UL45 homolog. ORF 15, the UL45 homologous
locus in EHV-1, is known to be expressed as a g-2 gene
that encodes a 0.9-kb mRNA that is 39-coterminal with
the gC transcript (Matsumura et al., 1993). To character-
ize the EHV-1 UL45 gene product, specific antisera were
generated and used to detect the protein in purified
virions or in lysates of infected cells. Synthesis, process-
ing, and subcellular localization of the UL45 protein were
examined. Finally, the role of the EHV-1 UL45 homolog in
EHV-1 replication in cell culture was assessed by char-
acterizing UL45 deletion mutants constructed from
EHV-1 strains RacH and RacL22 (Fig. 1). The EHV-1
modified live vaccine strain RacH was chosen in addition
FIG. 1. Diagram of constructs used in this study: shown is a BamHI m
The ORFs 15 and 16 of EHV-1 representing the UL45 and gC homolo
p45GFP1 (b) is described under Materials and Methods. TM, potentia
of the multiple cloning site of vector pTZ18R (Stratagene). Restriction sto the virulent wild-type EHV-1 strain RacL22 for the
generation of UL45 mutants to include a putative influ-ence of the EHV-1 UL45 on cell fusion in our studies.
RacH induces fusion of infected cells especially in cells
of equine origin. The amino acid sequence of the RacH
gB has been shown to carry several mutations compared
to wild-type EHV-1 gB sequences (Neubauer et al.,
1997b), and the mutated gB has been connected with the
distinct syncytial (syn) phenotype of RacH (Neubauer et
al., 1997a).
RESULTS
Identification of the EHV-1 UL45 protein
The rabbit antisera produced after immunization with
either the UL45 peptide (UL45-P) or the 6-His-tagged
UL45 protein (UL45-His) were tested for their ability to
react specifically with EHV-1 by Western blot analysis.
RacL22-infected cell lysates were harvested at 14 h p.i.,
subjected to SDS–PAGE, and incubated with the respec-
tive antibodies. Under denaturing conditions, both anti-
sera reacted specifically with at least three protein spe-
cies exhibiting Mrs of 32,000, 40,000, and 43,000 (Fig. 2).
To confirm the specificity of the antiserum, anti-UL45-P
was blocked by preincubation with the UL45-peptide
against which it had been produced. After preincubation,
the anti-UL45-P antiserum failed to react with any of the
previously identified proteins in RacL22-infected cells
EHV-1 strain RacL22 and a magnification of the BamHI-h fragment (a).
RFs are indicated. The construction of the plasmids pQE45 (c) and
embrane domain of UL45; N, putative N-glycosylation site; MCS, part
e indicated.ap of
gous O
l transm
ites ar(Fig. 2C), whereas after blocking with an irrelevant pep-
tide, the reactivity of the antiserum remained unaffected
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304 OETTLER, KAADEN, AND NEUBAUER(Fig. 2D). However, the binding of the antiserum to higher
Mr proteins that frequently reacted in uninfected- and
nfected-cell lysates was not specifically blocked by the
L45 peptide (Fig. 2C), and these reactions were con-
idered unspecific. Due to its apparent higher sensitivity,
he anti-UL45-His antiserum was chosen for most exper-
ments in this study.
From the analysis of the UL45 protein moieties in
nfected cells, it was concluded that the EHV-1 UL45
rotein is expressed as proteins of apparent Mrs of
32,000, 40,000, and 43,000 in infected cells. To further
analyze UL45 protein processing, RacL22-infected Ed-
min337 cells were harvested at 8 or 14 h p.i., lysed,
mixed with sample buffer without addition of 2-mercap-
toethanol, and subjected to SDS–PAGE without heating
at 95°C. Western blot analysis revealed additional pro-
FIG. 2. Western blot analysis of lysates of RacL22-infected Rk13 cells
(0 and 14 h p.i.). Proteins were separated by 12% SDS–PAGE, were
transferred to nitrocellulose, and were incubated with either anti-UL45-
His (A) or anti-UL45-P (B–D, horizontal line). In some blots, anti-UL45-P
was preincubated with either 50 mg of the UL45-peptide (C) or 50 mg of
an irrelevant peptide (D). Prestained molecular weight marker sizes
(Gibco, BRL) are indicated in thousands.
FIG. 3. Western blot analysis of lysates of RacL22-infected Rk13 cells
(0, 8, and 14 h p.i.). Samples were mixed with buffer without 2-mercap-
toethanol and were separated by 12% SDS–PAGE without prior boiling.
Blots were incubated with anti-UL45-His. Prestained molecular weight
marker sizes (Biolabs) are indicated in thousands.teins of Mr 60,000–90,000 that reacted specifically with
the UL45-His antibody and which became prominent
during infection (Fig. 3). The fact that these high-Mr
proteins contained UL45 protein led to the conclusion
that these bands arise by formation of UL45 homo- or
heterodimers linked by disulfide bonds.
Synthesis and processing of the EHV-1 UL45 protein
To determine the kinetics of UL45 expression, Ed-
min337 cells were infected at an m.o.i. of 5 with EHV-1
strain RacL22. Infected cell lysates were prepared at
different times postinfection, were adjusted to equal pro-
tein concentrations, and were subjected to Western blot
analysis. Parallel blots were probed with the anti EHV-1
glycoprotein B (gB) antibody 3F6 (Allen and Yeargan,
1987) or with anti-UL45-His. The results of this experi-
ment are shown in Fig. 4. Although the early–late (b2g)
gB was detected as early as 5 h p.i. (Fig. 4B), the EHV-1
UL45 protein could not be detected until 8 h p.i. (Fig. 4A).
It was noted that the intensity of the Mr 32,000 UL45
moiety increased #10 h p.i. Thereafter, the intensity of
he lower-Mr UL45 band decreased, whereas the inten-
ities of the UL45 proteins of Mr 40,000 and 43,000
increased with time p.i. (Fig. 4A).
The expression kinetics of the EHV-1 UL45-protein
was assessed further in experiments using PAA to block
viral DNA synthesis. Edmin337 cells were infected at an
m.o.i. of 5 with RacL22 and were incubated in the pres-
ence of various concentrations of PAA (0.1, 0.5, and 1.0
mg/ml medium). Infected cells were lysed at 14 h p.i. and
were analyzed by SDS–PAGE and Western blotting. Rel-
ative to the concentration of PAA added, the amount of
UL45 protein decreased and was absent in the presence
FIG. 4. Western blot analysis of Edmin337 cells infected with RacL22
(m.o.i. of 5) that were lysed at the indicated times after infection and
adjusted to 1 mg of protein/ml probe. After separation in 12% PAGE,
identical blots were reacted with anti-UL45-His (A) or anti EHV-1 gB
antibody 3F6 (B), respectively. Prestained molecular weight marker
sizes (Gibco, BRL) are indicated in thousands.of 0.5 mg of the drug. In contrast gB, which represents a
b2g protein, remained detectable even in the presence
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and the PAA experiments, it was concluded that EHV-1
UL45 is expressed as a true late (g-2) protein.
The EHV-1 UL45 protein is N-glycosylated and
represents a class II membrane glycoprotein
The following series of experiments addressed the
putative N- or O-glycosylation of the UL45 protein be-
cause the amino acid sequence of the EHV-1 UL45
protein carries a putative membrane anchor and three
N-glycosylation consensus sites that could theoretically
be used if the protein was present in a type II orientation
within membranes. In addition, glycosylation could ex-
plain the migration pattern of the UL45-specific proteins
observed in infected cell lysates. Initially, the possibility
of membrane association for the UL45 protein was ad-
dressed. RacL22-infected cells (m.o.i. of 5) were har-
vested at 14 h p.i. and separated into fractions (Bogner et
al., 1992). All fractions were adjusted to the same protein
concentrations and subjected to Western blot analysis.
gB-specific bands were detected with MAb 3F6 in nu-
clear as well as membrane fractions but not in the
soluble cytoplasmic fraction, thus confirming the identity
of the fractions (data not shown). With the anti-UL45-His
antibody, there was a clear reactivity in the fraction con-
taining cellular membranes, a weaker reactivity in the
nuclear fraction and no reactivity at all in the soluble
fraction (Fig. 6A). These data support an association of
the EHV-1 UL45 with cellular membranes.
Two approaches were taken to analyze the putative
N-glycosylation of the UL45 protein. First, Rk13 cells
were infected at an m.o.i. of 5 with RacL22 for 14 h in the
presence or absence of tunicamycin (Fig. 6B). Second,
infected cell lysates were treated with PNGase F (Fig.
6C). Western blots of the cell lysates treated as de-
scribed above were incubated with the anti-UL45-His
FIG. 5. Western blot analysis of Edmin337 cells that were infected
ith an m.o.i. of 5 of RacL22 in the presence of PAA in the concentra-
ions indicated (mg/mL). Cells were lysed at 14 h p.i. and subjected to
2% PAGE. Parallel blots were incubated with anti-UL45-His (A) or 3F6
B), respectively. Molecular weight marker sizes are indicated in thou-
ands.antibody or with anti-gB MAb 3F6 as a control. As ex-
pected, the electrophoretic mobility of gB-specific bandsincreased both after incubation with tunicamycin and
after enzymatic deglycosylation (data not shown). The
distinct pattern of UL45-specific bands disappeared after
incubation of infected cells in the presence of tunicamy-
cin and after enzymatic deglycosylation using PNGaseF,
and a single protein species of Mr 24,000 was detected
using the anti-UL45 antibody (Figs. 6B and 6C). UL45
protein processing was analyzed further by enzymatic
deglycosylation using EndoH, which removes high-man-
nose glycans. As shown in Fig. 6D, the Mr 32,000 UL45
protein was absent after EndoH treatment, whereas the
Mr 40,000 and 43,000 UL45 moiety remained unaffected.
Finally, enzymatic deglycosylation using a combination
of neuraminidase and O-glycosidase was performed. No
alteration of the electrophoretic mobilities of the various
UL45 protein moieties was observed, thereby excluding
addition of O-linked glycans to the UL45 polypeptide
(data not shown). The Mr 24,000 UL45 protein species
(Figs. 6B–6D) corresponded quite well to the predicted
Mr of 23,798 and was therefore interpreted to be the
nonglycosylated backbone of UL45.
The above observation that the EHV-1 UL45 protein is
modified by addition of N-linked carbohydrates is only
possible if the protein represents a type II transmem-
brane protein as reported for the HSV-2 UL45 homolog
(Cockrell and Muggeridge, 1998).
FIG. 6. Western blot analysis of Edmin337 cells that were infected
with an m.o.i. of 5 of RacL22. (A) Cells were separated into fractions at
14 h p.i. and subjected to 12% PAGE. CP, soluble cytoplasmatic fraction;
N, nuclear fraction; M, membrane fraction. (B) Cells were infected in the
presence of tunicamycin in the concentrations indicated or were lysed
in N-glycosidase F buffer at 14 h p.i. and incubated for 16 h at 37°C with
(10.1 U or 10.4 U) or without (1buf.) addition of N-glycosidas F (C). (D)
Other samples were treated with EndoH as described under Materials
and Methods. All lysates were subjected to 12% PAGE, and the blots
shown were incubated with anti-UL45-HIS. Molecular weights are
shown in thousands.
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virions
RacL22 and RacH virions were purified over a sucrose
cushion, checked for purity by electron microscopy, and
analyzed by Western blotting. Identical blots were
probed either with anti-UL45-His or with the anti EHV-1
gB MAb 3F6. In extracellular virions, only the 75,000 Mr,
ompletely processed large subunit (Sullivan et al., 1989)
of gB was detectable (Fig. 7B). In contrast, no signal with
the UL45-His antibody was obtained (Fig. 7A), even at
longer exposure times. The strength of the gB signal and
lack of UL45-specific reactivity in purified virus prepara-
tions suggest that the EHV-1 UL45 protein is not incor-
porated into extracellular EHV-1 virions.
EHV-1 UL45 is nonessential for virus growth in cell
culture
To investigate the role of EHV-1 UL45 in cell culture,
UL45 deletion mutants from strains RacL22 and RacH
were engineered. To this end, plasmid p45GFP1 was
inserted into the genomes of RacL22 and RacH, respec-
tively, by homologous recombination (Figs. 1A and 1B).
The resulting recombinant viruses, LD45 and HD45, were
purified to homogeneity on Rk13 cells by four rounds of
plaque purification. Similarly, the repaired viruses R-L45
and R-H45 were isolated after cotransfection of LD45 or
HD45 DNA with the 7348-bp BamHI-h fragment by se-
lection for nonfluorescing plaques.
All recombinant viruses, as well as the parental virus
strains, were characterized by Southern blot analysis.
Viral DNA from UL45-negative, repaired, and parental
viruses, i.e., RacL22, LD45, R-L45, RacH, HD45, and R-
H45 was prepared, digested with either BamHI or EcoRI,
and analyzed by Southern blotting. The correct insertion
of the GFP gene (LD45 and HD45), or the re-insertion of
the UL45 gene in the case of R-L45 and R-H45, was
FIG. 7. Western blot analysis of RacH and RacL22 virions purified
rom supernatants of infected cells (14 h p.i.) and of lysates of RacL22-
nfected Rk13 cells (12 h p.i.). Parallel blots were incubated with anti-
L45-His (A) or 3F6 (B). Molecular weight marker sizes are indicated in
housands.confirmed using probes specific for the GFP gene or the
UL45 gene (data not shown).
M
mThe fact that we were able to isolate HD45 and LD45
on Rk13 cells clearly demonstrated that UL45 is not
essential for virus replication in vitro. To further charac-
terize the growth properties of HD45 and LD45, a series
of experiments was conducted. First, expression of late
genes and the absence of the UL45 protein were ana-
lyzed in Rk13 cells infected at an m.o.i. of 5 with RacL22,
RacH, the UL45-negative viruses, or the repaired viruses.
Infected cell lysates (14 h p.i.) were analyzed by Western
blotting using the anti UL45-His antibody, anti-gB MAb
3F6, an anti-gD antibody, or anti gM-MAb B8. As shown
in Fig. 8, reactivity of gB, gD, and gM was detected
readily in lysates of cells infected with parental or with
UL45-negative viruses. These results indicated not only
that an equivalent amount of infected cells had been
used for the experiment but also that the production of
late, structural proteins such as gB, gD, or gM appeared
unaffected by the deletion of UL45. In contrast, UL45-
specific reactivity was detected in lysates of cells in-
fected with the parental viruses or the repaired viruses
but not in lysates of cells infected with LD45 or HD45,
thus demonstrating the absence of the UL45 gene in the
engineered mutants (Fig. 8).
Because the transcript of the gene adjacent to UL45,
the EHV-1 gC-gene, is 39-coterminal with the UL45 tran-
script (Matsumura et al., 1993), we sought to confirm that
expression of gC was not affected by the deletion of
UL45 and insertion of the GFP cassette. To this end, Rk13
cells in six-well plates were infected with 30 PFU of
parental, UL45-negative, or repaired viruses and were
analyzed by IIF using anti EHV-1 gC MAb 2A2 or anti-gB
MAb 3F6. It was demonstrated that gC- and gB-specific
reactivity were indistinguishable, irrespective of whether
LD45 and HD45 or any of the parental or repaired viruses
FIG. 8. Western blot analysis of Rk13 cells infected with RacL22,
HD45, LD45, or HDgM at an m.o.i. of 5. HDgM is a gM-negative EHV-1
Neubauer et al., 1997a) that was used as an additional control. Blots
ere incubated with anti-UL45-His (A), anti gB MAb 3F6 (B), anti gM
Ab B8 (C), or anti-gD antibody (D, anti 19mer). Molecular weight
arker sizes are indicated in thousands.
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concluded, therefore, that the replacement of 646 bp of
EHV-1 sequences by the GFP-expression cassette of
1487 bp did not influence the correct expression of the
adjacent gC gene.
To test whether deletion of the UL45 protein influences
viral entry, virus penetration assays were performed.
Because the UL45 protein had not been detected in
extracellular virions, no direct influence of the UL45 pro-
tein on virus entry was expected. Accordingly, the pen-
etration experiments demonstrated that HD45 and LD45
are able to enter Rk13 cells, and no significant difference
in the kinetics of virus penetration with either parental or
repaired viruses was observed (Fig. 9).
In the following experiments, single-step growth kinet-
ics of UL45-negative and parental or repaired viruses
were performed. Rk13 or Edmin337 cells in 24-well
plates were infected at an m.o.i. of 10 with the respective
viruses. Supernatants and infected cell pellets were har-
vested separately at various times p.i. (0, 3, 6, 8, 10, 12,
and 24 h). Supernatants were cleared of cellular debris
by low-speed centrifugation, and cells were subjected to
two rounds of freeze–thawing before cell-associated in-
fectivity was assayed. All virus titers were determined
individually on Rk13 cells in 24-well plates. The results
can be summarized as follows: With the single exception
of a 36-fold reduction in virus titers at 6 h p.i., cell-
associated infectivity of HD45 was reduced by less than
5-fold on Rk13 cells compared to titers of cells infected
with RacH (Fig. 10A), supporting the initial observation
that the UL45-negative viruses can replicate efficiently in
cell culture. In contrast, extracellular virus titers of HD45
were reduced by #140-fold (12 h p.i.) compared to those
of RacH (Fig. 10A). Similarly, intracellular virus titers of
cells infected with LD45 reached those of RacL22 at 24 h
(factor 0.56; Fig. 10B), whereas extracellular virus titers
FIG. 9. Penetration kinetics of RacH, HD45, RacL22, and LD45 into
k13 cells. Shown are means of three independent experiments. Stan-
ard deviations are indicated by error bars.were reduced by ;130-fold at 12 h p.i. (Fig. 10B). The
difference in extracellular virus titers between UL45-negative and parental or repaired viruses was even more
prominent at the beginning of the experiment (6 h), when
no extracellular infectivity was detected for the UL45-
negative viruses. In contrast, in supernatants of cells
infected with either wild-type or repaired viruses, virus
titers of #2.7 3 102 were observed. The data are illus-
trated in Fig. 10 for Rk13 cells only because the reduction
of extracellular virus titers of UL45-negative viruses on
Edmin337 cells was very similar to that observed on
Rk13 cells.
Following the single-step growth kinetics, the growth
properties of the UL45-negative viruses after infection of
Rk13 cells at different m.o.i.s were determined. The in-
tracellular and extracellular virus titers of RacH, RacL22,
HD45, LD45, R-H45, and R-L45 were determined at time
point 0 and at 12, 24, and 48 h p.i. The extracellular titers
of RacH, RacL22, or repaired viruses exceeded intracel-
lular virus titers between 12 and 24 h, whereas extracel-
FIG. 10. Replication of RacH, HD45, R-H45 (A) and RacL22, LD45 and
R-L45 (B) on Rk13 cells. Cells were infected with an m.o.i. of 10 and at
different time points postinfection, infectivity of supernatants (extracel-
lular) and cell associated infectivity (intracellular) was determined.
Shown are means of three independent experiments. Standard devia-
tions are hidden by symbols.
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virus titers at any time postinfection (data not shown).
Plaque phenotypes of HD45 and LD45, however, were
not significantly altered compared to plaques observed
after infection with parental or with repaired viruses on
Rk13 cells as well as on Edmin337 cells. Only when in
parallel cells in six-well plates were infected with the
respective viruses (50 PFU) and incubated without any
overlay for 3 days was a marked reduction in the ability
to infect the entire monolayer observed for the UL45
deletion mutants compared to parental and repaired vi-
ruses (data not shown).
Taken together, these results led to the conclusion that
the deletion of UL45 causes a massive defect in virus
egress although production of late genes and the ability
to spread from cell to cell appears unaffected.
DISCUSSION
In this communication, an initial characterization of the
EHV-1 UL45 protein is presented. The salient findings of
this study are: (i) the EHV-1 UL45 protein is a heavily
N-glycosylated integral type II membrane protein; (ii)
although expressed at late times postinfection and pro-
cessed in the Golgi network, it is not incorporated into
extracellular virions; and (iii) despite efficient replication
of UL45-negative viruses on noncomplementing cells,
deletion of UL45 affected viral egress reducing extracel-
lular virus titers by up to 250-fold compared to titers of
wild-type EHV-1.
The HSV-1, HSV-2, and the EHV-1 UL45-proteins are
definitely related, structurally as well as functionally. On
the one hand, they share not only a large internal hydro-
phobic domain but also a characteristic type II mem-
brane orientation that has been shown experimentally for
the HSV-2 (Cockrell and Muggeridge, 1998) and for the
EHV-1 homolog (this study). On the other hand, they
exhibit only very low amino acid identity (less than 25% to
either HSV-1 or -2—as determined using program gap of
the gcg software package), and the HSV-1 and HSV-2
homologs do not carry consensus N-glycosylation sites,
while the EHV-1 UL45 and most probably other homolo-
gous UL45-proteins form a new family of herpesviral type
II membrane glycoproteins.
The PrV US9 protein is a relatively well-studied tail-
anchored type II membrane protein that is thought to be
inserted into membranes posttranslationally (Brideau et
al., 1998, 1999). The EHV-1 UL45 protein, however, is an
integral membrane protein and is inserted cotranslation-
ally into the endoplasmatic reticulum where glycosyla-
tion as well as formation of disulfide-linked di- and oli-
gomers is observed. The UL45-containing protein spe-
cies of higher Mr, which were demonstrated in this study,
ost probably represent homodimers as similar UL45-
pecific oligomers are observed in cells expressing the
HV-1 UL45 protein only (data not shown). In addition,the Mrs of the UL45 oligomers correspond quite well to
calculated molecular weights of dimers of the primarily
and fully processed glycoproteins. As there are nine
cystein residues present in the amino acid sequence of
the EHV-1 UL45, formation of homodimers by means of
disulfide bonds is very likely. Final protein processing
takes place in the Golgi apparatus, paralleled by the
occurrence of EndoH-resistant forms of the UL45 protein.
The occurrence of more then one EndoH-resistant form
indicates that the UL45 protein undergoes several gly-
coforms while passing through the Golgi apparatus. Tak-
ing into account that N-glycosylation of only three pos-
sible consensus sites leads to an apparent shift in the Mr
of ;20,000, glycosylation of the EHV-1 UL45 protein
seems to be very complex. This complexity could also
explain the appearance of additional UL45 specific
bands when the treatment of the lysates of infected cells
is varied, for example, as seen in Fig. 3, where various
UL45 reactive proteins were detected between 32 and 45
kDa.
Technical problems, such as insufficient sensitivity of
our antibody, cannot be excluded as the reason for fail-
ure to detect UL45 protein in purified extracellular viri-
ons. However, this is unlikely for the following reasons: It
was not possible to detect UL45 proteins in numerous
virion preparations, all of which contained at least 60%
enveloped particles and were strongly reactive with the
control antibody 3F6. This observation was corroborated
by the fact that the UL45-negative viruses did not show
an virus entry phenotype, although the latter could of
course also be seen in a structural protein that simply
does not function in virus entry. Therefore, the possibility
that the EHV-1 UL45 protein represents a fully processed
protein that is expressed late in infection and present in
the TGN but is still not incorporated into virions has to be
considered. It could be speculated that the UL45 protein
may lack a signal necessary for the incorporation into
extracellular virions or that it might be directed to another
subcellular compartment after having exerted its function
in virus maturation and egress. Consequently, one of our
future aims will be to study the subcellular localization of
the EHV-1 UL45 protein, e.g., degradation in lysosomes,
at very late times postinfection.
The functional characterization of the UL45-negative
EHV-1 in vitro indicated that the UL45 protein facilitates
virus egress. First, it was shown in virus growth kinetics
that the production of extracellular infectivity by the
UL45-negative viruses was particularly reduced. Second,
it was demonstrated that HD45 and LD45 were able to
form plaques and infect neighboring cells but were im-
paired in the fast spread of infectivity throughout an
entire cell monolayer. Taking into account that the ability
of intracellular as well as extracellular UL45-negative
virions to infect cells from outside is well conserved, the
reason for the observed reduction in extracellular infec-
tivity must be based on a reduction in a late step in the
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309EHV-1 UL45 PROTEIN IDENTIFICATION AND CHARACTERIZATIONvirus replication cycle. A general reduction in the effi-
ciency of envelopment and/or transport of virions
through and out of the cell could explain the marked
reduction of extracellular titers paralleled by a slight
reduction of intracellular titers. It has to be stressed at
this point that no accumulation of infectious viruses in
infected cells was observed that would allow the con-
clusion of the involvement of UL45 in a post-Golgi trans-
port step only. That a nonstructural protein expressed
late in infection is involved in virus egress processes
seems consequent. However, the inability to confirm a
role for EHV-1 UL45 in syncytia or generally in plaque
formation, as has been shown for the HSV-1 UL45 prod-
uct (Haanes et al., 1994; Visalli and Brandt, 1991), was a
urprise. Of course it has to be remembered that only
wo different cell systems in vitro were considered: Ed-
in337 cells, a permanent cell line of equine origin; and
k13 cells, a rabbit cell line. The phenotype observed
ould possibly differ in another cell system. Additionally,
he gB of RacH carries several mutations that could
nfluence a putative interaction of gB and UL45 in syn-
ytia formation. Last but not least, EHV-1 is not HSV-1,
nd UL45 could simply play another role in the EHV-1
ystem. By analyzing the expression of gC we were able
o exclude an influence of a reduced gC expression on
he phenotype of our UL45-negative viruses. A sufficient
xpression of gC was again supported by the fact that
D45 and LD45 were able to enter cells, whereas the
entry of gC-negative EHV-1 is severely impaired (Oster-
rieder, 1999). Therefore, in contrast to the studies on
HSV-1 UL45 (Visalli and Brandt, 1991), the results re-
ported here can only be accounted for by the deletion of
UL45 and thus represent the first thorough analysis of a
UL45-negative herpesvirus in vitro.
MATERIALS AND METHODS
Plasmids
To express a portion of the UL45 gene as a 6-His-
fusion protein, the predicted hydrophilic portion of the
UL45 ORF (bases 315–657) (Telford et al., 1992) was
amplified by PCR and inserted into vector pQE32 (Qia-
gen) (Fig. 1C). Correct amplification of the PCR product
was confirmed by sequence analysis (MWG Biotech).
The EHV-1 BamHI-h fragment in vector pTZ18R (Strat-
agene) (Osterrieder, 1999) was used for construction of
UL45 knock-out plasmid p45GFP1 (Fig. 1B). After re-
moval of one NruI site by SpeI and XbaI digestion (the
latter in the multiple cloning site of pTZ18R) and subse-
quent religation, the majority of the UL45-gene was re-
moved by digestion with BsmI and NruI (leaving the
arboxylterminal 117 bp of UL45). A GFP-expression cas-
ette released from plasmid pEGFP-C1 (Clontech) using
smI and NsiI was inserted in parallel transcriptional
rientation after blunt end modification of the NsiI site.
he resulting plasmid p45GFP1 is thus carrying theormer 5591-bp BamHI–SpeI fragment of EHV-1 but with
2% of the UL45 gene (542 bp) plus 106 bp of the
receding noncoding region removed and substituted by
he GFP cassette (Fig. 1B).
ells and viruses
The wild-type EHV-1 strain RacL22 and its attenuated
ell culture derivative RacH (Hu¨bert et al., 1996) were
ropagated in equine dermal cell line Edmin337 or on
abbit kidney cell line Rk13 (Neubauer et al., 1997b). All
ell lines were maintained in minimal essential medium
upplemented with 10% fetal calf serum.
eneration of recombinant viruses
The UL45-negative EHV-1 cells were generated by
otransfection of Rk13 cells with 5 mg of plasmid
p45GFP1 (Fig. 1b) and 1–2 mg of DNA of RacH or
RacL22, respectively. Supernatants of transfected cells
were plated on Rk13 cells and GFP-positive fluorescing
virus plaques, detected using an inverted fluorescence
microscope (Axiovert, Zeiss), were isolated. Recombi-
nant viruses were purified by four rounds of plaque
isolation. Repaired viruses were generated by cotrans-
fection of the BamHI-h fragment with DNA of the UL45-
negative viruses. Recombinants were isolated by selec-
tion for nonfluorescing virus plaques.
Purification of extracellular virions
Edmin337 cells were infected at a m.o.i. of 5. At 14 h
p.i., supernatants of infected cells were harvested. Cell
detritus was removed by low-speed centrifugation. The
virus suspension was layered carefully on a 30% sucrose
cushion and centrifuged for 3 h at 23,000 g in a Beckman
SW 28 rotor. The resulting pellet was resuspended in
medium, and the centrifugation was repeated. The viri-
ons were resuspended in PBS, and the purity of virion
preparations was examined by electron microscopy.
Southern blot analysis
Viral DNA was prepared from Rk13 cells infected with
the various viruses. DNA was digested with the indicated
restriction endonucleases, and the resulting fragments
were transferred onto positively charged nylon mem-
branes after separation in an 0.8% agarose gel, as pre-
viously described (Osterrieder et al., 1996; Neubauer et
al., 1997b). UL45 sequences released from pC45 (a plas-
mid carrying the UL45 ORF only) and the GFP sequences
from pEGFP-C1 were labeled with digoxigenin 11-dUTP
(Roche Molecular Biochemicals) by random priming and
used as UL45- and GFP-specific probes. DNA hybrids
were detected using an anti-digoxigenin alkaline phos-
phatase conjugate (Roche Molecular Biochemicals) and
visualized with nitroblue tetrazolium and 5-bromo-4-
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310 OETTLER, KAADEN, AND NEUBAUERchloro-3-indolyl phosphate according to the manufactur-
er’s instructions.
Antibodies
The monoclonal anti EHV-1-gB antibody 3F6 (Allen and
Yeargan, 1987), anti-EHV-1 gC monoclonal 2A2 (Oster-
rieder, 1999), anti-EHV-1-gD polyclonal anti-19mer rabbit
antibody (Flowers and O’Callaghan, 1992), and anti EHV-
1-gM monoclonal antibody B8 (Day, 1999) were used in
this study. To generate UL45-specific antibodies, two
different approaches were taken. First, a peptide corre-
sponding to amino acids 32–56 of the deduced amino
acid sequence of UL45 (Telford et al., 1992) was synthe-
sized (MWG Biotech) (Fig. 1C). The peptide was coupled
to keyhole limpet hemocyanin (Sambrook et al., 1989)
nd 200 mg of the coupled peptide was used for immu-
ization of two rabbits. Second, a 6-His-tagged fusion
rotein (Fig. 1C) was expressed in Escherichia coli strain
15 and was purified using the Qiaexpress type IV
xpression and purification system following the manu-
acturer’s instructions (Qiagen). The quantity and quality
f the purified protein were confirmed by sodium dodecyl
ulfate (SDS)–polyacrylamide gel electrophoresis (PAGE)
nd subsequent Coomassie blue staining or Western
lot analysis using the RGS-His Antibody (Qiagen). Two
abbits were immunized five times at 6-week intervals
ith 50–100 mg of the purified protein.
Western blotting and indirect immunofluorescence
Edmin337 or Rk13 cells were infected at an m.o.i. of 5
with the respective viruses and cells were lysed at the
indicated time points p.i. Lysates were adjusted to 1
mg/ml protein (BCA protein assay; Pierce), and sample
buffer containing 5% 2-mercaptoethanol was added
(Sambrook et al., 1989). Samples were heated at 95°C for
5 min, and proteins were separated on SDS 12 or 15%
polyacrylamide gels. Separated proteins were blotted
onto nitrocellulose filters (Towbin et al., 1979). Free bind-
ng sites on nitrocellulose membranes were blocked with
0% nonfat dry milk in PBS containing 0.05% Tween 20
Sigma). Antibodies were added at the indicated concen-
rations for 1 h at RT. Antibody binding was visualized
sing anti-mouse or anti-rabbit immunoglobulin G (IgG)
eroxidase conjugate (Sigma) followed by ECL detection
Pharmacia-Amersham).
For indirect immunofluorescence analysis (IIF), Rk13
ells infected for 14 h with the indicated viruses were
ixed with 80% acetone. Unspecific binding was blocked
ith PBS containing 10% FCS for 45 min. After two wash-
ng steps with PBS, cells were incubated with the pri-
ary antibody for 30 min, washed again, and incubated
or 30 min with the anti-rabbit or anti-mouse IgG Alexa
46 or Alexa 488 conjugates (Molecular Probes). Afterwo final washing steps, probes were analyzed by fluo-
escence microscopy (Axiovert/Zeiss).Analysis of protein synthesis and deglycosylation
experiments
Inhibition of DNA synthesis, using phosphonoacetic
acid (PAA), was achieved by addition of the drug (0.1, 0.5,
or 1 mg/ml of medium) to Rk13 cells infected at an m.o.i.
of 5 with RacL22. Infected cells were incubated for 14 h
before cell lysates were prepared and subjected to SDS–
PAGE.
To inhibit cotranslational N-glycosylation, Rk13 cells
were infected at an m.o.i. of 5 with RacL22 and incubated
for 14 h in the presence of tunicamycin (1.0, 5.0, or 10.0
mg/ml medium) (Roche Molecular Biochemicals).
N-linked carbohydrates were removed using N-glycosi-
dase F (peptide-N-glycosidase F, Roche Molecular Bio-
chemicals). At 14 h p.i., cells were resuspended in N-
glycosidase F buffer (Osterrieder et al., 1997) and incu-
bated for 16 h in the presence or absence of 0.1 or 0.4 U
of N-glycosidase F. Endoglycosidase H (endo-b-N-
acetylglucosaminidase H, Roche Molecular Biochemi-
cals,) was applied for 16 h at 37°C at 20 mU/100 ml of
infected cell lysate in a buffer containing Na3PO4 (50
M), SDS (0.2%), 2-mercaptoethanol (1%), and phenyl-
ethylsulfonyl fluoride (PMSF, 0.5 mM). O-glycosylation
as analyzed by adding 2 U of neuraminidase (Roche
Molecular Biochemicals) to cells that had been infected
for 14 h (RacL22), pelleted and freeze–thawed, broken by
ultrasonic treatment, and resuspended in a sodium ac-
etate (0.3 M; pH 5.2) and calcium chloride (0.1 M) solu-
tion. After 2 h incubation with neuraminidase at 37°C,
proteins were pelleted and subsequently resuspended in
Tris–phosphate buffer (20 mM, pH 7.4) and digested with
2 U of O-glycosidase (16 h, 37°C) (Roche Molecular
Biochemicals).
Fractionation of cells
Fractionation of cells was as described by Bogner et
al. (1992). Briefly, Rk13 cells were infected with RacL22 at
an m.o.i. of 5 for 14 h, washed with PBS, pelleted, and
resuspended in fractionation buffer (5 mM Na phos-
phate, pH 7.5, 2 mM MgCl2, 0.5 mM CaCl2, 1 mM PMSF),
and cells were broken by ultrasonic treatment. After
addition of sucrose (ad 0.3 M), nuclei and cell detritus
were pelleted at 800 g (10 min, pellet 1), followed by
centrifugation at 10,000 g (10 min). The collected super-
natant was separated by centrifugation at 100,000 g (1 h,
4°C) into a fraction containing the plasma membranes as
well as vesicles from the endoplasmatic reticulum and
Golgi network (pellet 2), and into a fraction (supernatant)
containing the soluble components of the cytoplasm.
Pellet 1 was resuspended in fractionation buffer, and
nuclei were separated from remaining intact cells and
cell detritus by centrifugation over a sucrose cushion
(1.62 M). Finally, nuclei were lysed in fractionation buffer
by addition of 0.5% Triton X-100.
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311EHV-1 UL45 PROTEIN IDENTIFICATION AND CHARACTERIZATIONPenetration assays
Penetration assays were performed as previously de-
scribed (Osterrieder et al., 1996; Neubauer et al., 1997b).
Briefly, Rk13 cells grown on six-well plates were prein-
cubated at 4°C for 30 min, infected with 100 PFU of the
respective viruses, and incubated at 4°C for 90 min to
allow virus absorption. The temperature was adjusted to
37°C, and at different times after temperature shift, ex-
tracellular virus was inactivated using a citrate buffer (pH
3.0) for 2 min. The percentage of plaques present after
citrate treatment relative to the number of plaques
present after control treatment (PBS) was determined.
Virus growth kinetics and plaque size measurements
Rk13 or Edmin337 cells seeded in 24- or 6-well plates
were infected with the indicated viruses. After a 2-h
absorption period at 4°C, viruses were allowed to pen-
etrate for 90 min before remaining extracellular virus was
inactivated using a citrate buffer (pH 3.0). At the indicated
times, parallel samples of supernatants and infected
cells were harvested. Titers of intracellular and extracel-
lular virus were compared at each time point by plaque
titration on Rk13 cells in 24-well plates. Plaque sizes on
Rk13 or Edmin337 cells were determined as follows.
Cells seeded on six-well plates were infected with 50
PFU per well of the respective viruses. Three days
postinfection, the sizes of the plaques were determined
by measuring the maximal diameter of 300 randomly
selected plaques in the presence or absence of 0.25%
methylcellulose.
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